SMA Niv denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for sma niv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied This Claim — and Why It's Appealable

A quantity-limits denial for non-invasive ventilation (NIV) in spinal muscular atrophy (SMA) usually arises when the hours of daily use, the number of units dispensed, or the frequency of supply replacements exceeds the default parameters in Humana's coverage policy. In SMA, respiratory muscle weakness typically requires ventilator support patterns that differ substantially from other diagnoses — the "standard" quantity limit may be clinically inadequate, making this denial highly appealable on medical-necessity grounds.

## Your Federal Appeal Rights

ACA §2719 guarantees the right to an internal appeal and then an independent external review by an IRO outside Humana's control. ERISA §503 adds the "full and fair review" standard for employer-sponsored plans. The external review window is generally four months from the denial date. Expedited external review is available when the treating physician certifies that the quantity limit materially endangers the patient — a reasonable certification in advanced SMA respiratory failure.

## Concrete Appeal Steps

1. Get the denial in writing with the specific quantity parameter that was exceeded and the policy provision invoked. 2. Request Humana's coverage criteria for home ventilator support quantity limits — the plan must disclose these. 3. File a Level 1 internal appeal arguing that the patient's clinical condition constitutes a medical exception to the standard limit. 4. Escalate to external review if Level 1 is upheld; IROs applying clinical-necessity standards regularly overturn rigid quantity-limit denials. 5. File a concurrent state complaint if the insurer misses its response deadline.

## Documentation to Gather

• Diagnosis and functional status: Genetic confirmation of SMA; specialist documentation of the degree of respiratory muscle involvement and functional decline trajectory.
• Usage justification: A detailed statement from the prescribing physician or respiratory therapist explaining why the quantity dispensed is medically required — referenced to the patient's specific ventilator settings, usage logs, and clinical response.
• Prior treatment history: Any previous NIV trials at lower quantities, with documented clinical outcomes demonstrating inadequacy.
• Clinical severity evidence: Pulmonary function data, sleep study findings, blood gas trends, and any acute respiratory events — framed as supporting the prescriber's judgment that a higher quantity is necessary.
• Prescriber medical-necessity letter: Letter referencing the FDA-cleared device labeling and the applicable guideline organization (e.g., ATS or AAN neuromuscular respiratory guidelines), explicitly addressing why the standard quantity limit is insufficient for this patient.

## Criteria-Mapping Structure

Build a table: left column lists each element of Humana's quantity-limit exception criteria; right column cites the specific chart documentation satisfying each element. Quantity-limit exception appeals succeed most often when the reviewer can see, in one document, that every exception criterion is met with direct evidence — leave no element unaddressed.